BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have refractory non-Hodgkin's lymphoma.

Timeline

Start

2002-01

Primary completion

—

Completion

—

Drugs

Indications